Trial Profile
Phase II Study of the Targeted Mutant IDH2 Inhibitor Enasidenib in Combination With Azacitidine for Relapsed/Refractory AML
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Enasidenib (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia
- Focus Therapeutic Use
- 15 Aug 2023 Planned End Date changed from 20 Sep 2023 to 20 Sep 2025.
- 15 Aug 2023 Planned primary completion date changed from 20 Sep 2023 to 20 Sep 2025.
- 05 Dec 2022 Planned primary completion date changed from 20 Sep 2022 to 20 Sep 2023.